Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
50-99-7
Molecular formula
C6H12O6
Molecular weight
180.16 g/mol
Drug class
Monosaccharide carbohydratemetabolic substrate and intravenous energy/electrolyte vehicle
Mechanism of action
Enters glycolysis and oxidative phosphorylation to produce ATP. Intravenous glucose raises blood glucose and provides substrate for cellular energy metabolism; in hyperinsulinaemic states it counteracts hypoglycaemia.
Indications / reported uses
Treatment of hypoglycaemia using oral or intravenous glucose, with concentration and route chosen according to severity and clinical setting
Intravenous glucose solutions provide fluid and carbohydrate calories and may be used in perioperative or parenteral nutrition settings; these are formulation-specific uses
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Glucose PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Glucose Permitted Daily Exposure (PDE) report (the Glucose PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Glucose Occupational Exposure Limit (OEL) report (the Glucose OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.